arrow
P

Paolo Cameli

University of Siena
H指数:38
被引数:6,300

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of dosing on functional and clinical outcomes of patients with progressive pulmonary fibrosis treated with Nintedanib: data from a real-world, multicentric, Italian study

Nintedanib治疗进行性肺纤维化患者中给药方案对功能和临床结局的影响:一项真实世界、多中心、意大利研究的数据

2025-11-200
PRE
Multinational Survey on the Symptom Approach to Diagnosis and Therapy Adopted by Physicians in the Treatment of Gastrointestinal Sarcoidosis

多国调查:医师在治疗胃肠道肉芽肿病时采用的基于症状的诊断与治疗方法

2025-11-200
OAAI
Serum ferritin as a specific biomarker of anti-MDA5-interstitial lung disease: a multicenter, case–control study in observational and validation datasets

血清铁蛋白作为抗MDA5-间质性肺病的特异性生物标志物:一项在观察和验证数据集中的多中心、病例对照研究

2025-07-150
PRE
Effectiveness of Nintedanib in Progressive Pulmonary Fibrosis Assessed by Progression Criteria: An Italian, Observational, Multicenter Study

尼达尼布在进展性肺纤维化中的有效性评估:基于进展标准的意大利、观察性、多中心研究

Lung
IF3.9
2025-07-080
PRE
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study

苯瑞利珠单抗在伴有或不伴有伴鼻息肉的慢性鼻-鼻窦炎的严重嗜酸性哮喘患者中的疗效持久性:ANANKE研究的事后分析

2025-03-200
OA
Objective Effects and Patient Preferences for Ambulatory Oxygen in Fibrotic Interstitial Lung Disease With Isolated Exertional Hypoxaemia: A Placebo-Controlled 6-Minute Walk Test Study

客观效果及患者偏好:在伴有孤立性运动性低氧血症的纤维化间质性肺疾病中使用便携式氧疗的随机对照6分钟步行试验研究

2025-03-110
OAAI
Prevalence and Predictors of Response to Antifibrotics in Long-Term Survivors with Idiopathic Pulmonary Fibrosis

特发性肺纤维长期存活者对抗纤维化药物反应的发生率及预测因素

LUNG
IF3.9
2025-02-250
PRE